New drug combo shows promise for Hard-to-Treat blood cancers

NCT ID NCT02328014

Completed Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Participants had to have a confirmed diagnosis and be in relatively good health. The study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm non-Hodgkin lymphoma plasma cell myeloma precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-ALL MULTIPLE MYELOMA NON-HODGKINS LYMPHOMA

Contacts and locations

Locations

Research Site

Orange, California, 92868, United States
Research Site

Bethesda, Maryland, 20892, United States
Research Site

Rochester, New York, 14642, United States
Research Site

Portland, Oregon, 97239, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Austin, Texas, 78705, United States
Research Site

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.